BRIEF-Cytori Therapeutics says ADRESU incontinence trial hits 50 pct enrollment milestone
Dec 14 Cytori Therapeutics Inc :
* Cytori pivotal ADRESU incontinence trial hits 50 pct enrollment milestone
* thus far ADRESU therapy has been well-tolerated by study patients, and we currently anticipate full enrollment in mid-2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
Allianz expects loss of around $224 million from sale of OLB
FRANKFURT, June 25 German insurer Allianz expects to book a loss of around 200 million euros ($224 million) from the sale of private bank Oldenburgische Landesbank to U.S. private equity firm Apollo, it said on Sunday.